Q2 2024 Medivir AB Earnings Call Transcript
Key Points
- Medivir AB (FRA:MVR0) presented strong data for the Fostrox Lenvima combination at the ESMO GI Congress, showing superior efficacy in second-line liver cancer.
- The liver-targeted approach of Fostrox demonstrated the ability to kill cancer cells without negatively impacting normal liver function.
- The median time to progression for the Fostrox Lenvima combination was 10.8 months, which is significantly longer than other second-line treatments.
- The company is accelerating the Fostrox development program according to plan, with preparations for a Phase 2b study underway.
- Financial performance for Q2 was in line with expectations, with a cash position of around $127 million, providing a runway into Q1 2025.
- The company faces a challenging funding situation, with cash expected to last only until the end of Q1 2025.
- Costs are expected to increase in the next three quarters due to ongoing clinical and CMC investments.
- There is still no confirmed partner for the Fostrox development program, which is critical for future progress.
- The initiation of the Phase 2b study has been delayed and is now expected to start in the first half of 2025.
- The patient population in the Fostrox Lenvima study includes third-line patients, which may complicate the interpretation of results.
Thank you very much and a warm welcome, everyone to the quarter two results webcast here at Medivir. I hope everyone has had a great summer as we sort of kick off again, after a warm and long summer vacation.
Here at Medivir of you, we closed out quarter two sort of at the beginning of the summer on a very high note when we presented sort of a strong data set for the first structure, Lenvima combination at ESMO GI Congress in Munich, and we will come back to that and share a bit more details today in terms of the data presented. And how we are now working forward with the Fostrox development program.
So important information which you will find as you access the presentation on the website. As mentioned in quarter two we were able to share a very exciting data set at ESMO GI, where we can see or could see for the Fostrox Lenvima combination, a superior efficacy compared with what has been shown in previous published studies in the second-line liver cancer space.
Equally important, we could confirm in that data set, and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
